JUN and hepatocellular carcinoma: Since lack of T cell activation and loss of effector function represent hurdles for successful TCR-T cell therapy (31), we studied whether overexpression of c-Jun would generate better expansion, improve effector functions, and increase persistence of the AFP158 specific TCR T cells in treating HCC xenografts.